Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial
Nina Wressnigg(Valneva (Austria)), Wolfgang Bender(Valneva (Austria)), Oliver Zoihsl(Valneva (Austria)), Nicole Bézay(Valneva (Austria)), Romana Hochreiter(Valneva (Austria)), Andrea Fritzer(Valneva (Austria)), Martina Schneider(Valneva (Austria)), Irena Corbic Ramljak(Valneva (Austria)), Susanne Eder-Lingelbach(Valneva (Austria)), Anton Klingler, Julian Larcher‐Senn, Katrin Dubischar(Valneva (Austria)), Urban Lundberg(Valneva (Austria)), Karen Lingnau(Valneva (Austria)), Andreas Meinke(Valneva (Austria))
Cited by 104
Related Papers
Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells
|Immunity|2010|539
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
|Nature Medicine|2002|328
Drosophila Stardust is a partner of Crumbs in the control of epithelial cell polarity
|Nature|2001|273
Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies
|The Journal of Experimental Medicine|2007|271